Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India

BACKGROUND: Cytokine storm triggered by Severe Coronavirus Disease 2019 (COVID-19) is associated with high mortality. With high Interleukin -6 (IL-6) levels reported in COVID-19 related deaths in China, IL-6 is considered to be the key player in COVID-19 cytokine storm. Tocilizumab, a monoclonal ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Gokhale, Yojana, Mehta, Rakshita, Kulkarni, Uday, Karnik, Nitin, Gokhale, Sushant, Sundar, Uma, Chavan, Swati, Kor, Akshay, Thakur, Sonal, Trivedi, Trupti, Kumar, Naveen, Baveja, Sujata, Wadal, Aniket, Kolte, Shaonak, Deolankar, Aukshan, Pednekar, Sangeeta, Kalekar, Lalana, Padiyar, Rupal, Londhe, Charulata, Darole, Pramod, Pol, Sujata, Gokhe, Seema Bansode, Padwal, Namita, Pandey, Dharmendra, Yadav, Dhirendra, Joshi, Anagha, Badgujar, Harshal, Trivedi, Mayuri, Shah, Priyanshu, Bhavsar, Prerna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934984/
https://www.ncbi.nlm.nih.gov/pubmed/33673818
http://dx.doi.org/10.1186/s12879-021-05912-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934984/
https://www.ncbi.nlm.nih.gov/pubmed/33673818
http://dx.doi.org/10.1186/s12879-021-05912-3

Ejemplares similares